Mirum Pharmaceuticals, Inc. (MIRM) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -860.21M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-860.21M | (m) |
| 2026-03-31 | (m) | $-798.84M | (m) |
| 2025-12-31 | (m) | $-23.36M | (m) |
| 2025-09-30 | (m) | $-41.42M | (m) |
| 2025-06-30 | (m) | $-58.56M | (m) |
| 2025-03-31 | (m) | $-77.34M | (m) |
| 2024-12-31 | (m) | $-87.94M | (m) |
| 2024-09-30 | (m) | $-99.81M | (m) |
| 2024-06-30 | (m) | $-109.16M | (m) |
| 2024-03-31 | (m) | $-158.56M | (m) |
| 2023-12-31 | (m) | $-163.41M | (m) |
| 2023-09-30 | (m) | $-164.19M | (m) |
| 2023-06-30 | (m) | $-176.31M | (m) |
| 2023-03-31 | (m) | $-129.19M | (m) |
| 2022-12-31 | (m) | $-135.66M | (m) |
| 2022-09-30 | (m) | $-41.69M | (m) |
| 2022-06-30 | (m) | $-53.09M | (m) |
| 2022-03-31 | (m) | $-70.06M | (m) |
| 2021-12-31 | (m) | $-83.99M | (m) |
| 2021-09-30 | (m) | $-178.74M | (m) |
| 2021-06-30 | (m) | $-153.13M | (m) |
| 2021-03-31 | (m) | $-132.49M | (m) |
| 2020-12-31 | (m) | $-103.27M | (m) |
| 2020-09-30 | (m) | $-84.02M | (m) |
| 2020-06-30 | (m) | $-77.60M | (m) |
| 2020-03-31 | (m) | $-67.91M | (m) |
| 2019-12-31 | (m) | $-52.55M | (m) |
| 2019-09-30 | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |